Natalie Cureton

Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy

Natalie Cureton, I. P. Korotkova, Bernadette Baker et al. · Theranostics · 2017 · 101 citations · Full text

Medicine, Obstetrics, Pharmacology +17

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana R�os et al. · Cancer Research · 2023 · 60 citations · Full text

Medicine, Oncology, Pharmacology +16

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors

Shanade Dunn, Cath Eberlein, Jason Yu et al. · Oncogene · 2022 · 34 citations · Full text

Medicine, Oncology, Pharmacology +17

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

Thomas G. Hayhow, Beth Williamson, Mandy Lawson et al. · Communications Biology · 2024 · 22 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists

James S. Scott, Darren Stead, Bernard Barlaam et al. · Journal of Medicinal Chemistry · 2023 · 17 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16